Home » Stocks » IPHA

Innate Pharma S.A. (IPHA)

Stock Price: $4.40 USD 0.00 (0.00%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $4.38 -0.02 (-0.46%) Apr 16, 4:00 PM
Market Cap 349.63M
Revenue (ttm) 96.42M
Net Income (ttm) -23.32M
Shares Out 78.97M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $4.40
Previous Close $4.40
Change ($) 0.00
Change (%) 0.00%
Day's Open 4.36
Day's Range 4.36 - 4.40
Day's Volume 2,239
52-Week Range 3.55 - 8.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Marseille, March 16, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conferen...

1 month ago - GlobeNewsWire

MARSEILLE, France, March 16, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a ...

1 month ago - GlobeNewsWire

MARSEILLE, France, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marc...

1 month ago - GlobeNewsWire

Marseille, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Fina...

1 month ago - GlobeNewsWire

MARSEILLE, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior mana...

2 months ago - GlobeNewsWire

Marseille, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management t...

2 months ago - GlobeNewsWire

Innate Pharma SA's (NASDAQ: IPHA) ongoing TELLOMAK Phase 2 trial, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit ad...

2 months ago - Benzinga

TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated

2 months ago - GlobeNewsWire

Marseille, Feb. 09, 2021 (GLOBE NEWSWIRE) -- TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated

2 months ago - GlobeNewsWire

Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021

2 months ago - GlobeNewsWire

Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021

2 months ago - GlobeNewsWire

MARSEILLE, France, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decisi...

3 months ago - GlobeNewsWire

Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision to pr...

3 months ago - GlobeNewsWire

MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior mana...

3 months ago - GlobeNewsWire

Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management t...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 22, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "C...

3 months ago - Newsfile Corp

Investors with losses are encouraged to contact the firm before December 22, 2020; click here to submit trade information Investors with losses are encouraged to contact the firm before December 22, 202...

3 months ago - GlobeNewsWire

LOS ANGELES, Dec. 21, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innate Pharma S.A. ("Innate" or "the...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - December 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...

3 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA) and cert...

3 months ago - Business Wire

New York, New York--(Newsfile Corp. - December 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...

3 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...

4 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action fil...

4 months ago - Business Wire

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September ...

4 months ago - PRNewsWire

BENSALEM, Pa., Dec. 14, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on beha...

4 months ago - PRNewsWire

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA).   Such investors are advised to...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 an...

4 months ago - GlobeNewsWire

MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US and ...

4 months ago - GlobeNewsWire

Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US and EU comme...

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 9, 2020) -   Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10,...

4 months ago - Newsfile Corp

LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed ...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from ...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are advised to c...

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...

4 months ago - Newsfile Corp

Phase 2 expansion cohort data supports ongoing Phase 3 trial Phase 2 expansion cohort data supports ongoing Phase 3 trial

4 months ago - GlobeNewsWire

NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA). Such investors are advised to contac...

4 months ago - PRNewsWire

MARSEILLE, France, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar:

4 months ago - GlobeNewsWire

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8...

4 months ago - PRNewsWire

LOS ANGELES, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed ...

4 months ago - GlobeNewsWire

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from ...

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - November 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...

4 months ago - Newsfile Corp

Marseille, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash position for the ...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September ...

5 months ago - PRNewsWire

Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Priority Medicines (PRIME) designation supports the poten...

5 months ago - GlobeNewsWire

MARSEILLE, France, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that members of its senior man...

5 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - November 9, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, ...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 6, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Co...

5 months ago - Newsfile Corp

BENSALEM, Pa.--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

5 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

5 months ago - Business Wire

About IPHA

Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the trea... [Read more...]

Industry
Biotechnology
IPO Date
Oct 17, 2019
CEO
Mondher Mahjoubi
Country
France
Stock Exchange
NASDAQ
Ticker Symbol
IPHA
Full Company Profile

Financial Performance

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Innate Pharma stock is "Buy." The 12-month stock price forecast is 7.30, which is an increase of 65.91% from the latest price.

Price Target
$7.30
(65.91% upside)
Analyst Consensus: Buy